U.S Domestic
Available Domestic
Lab Tested
Axiolabs Tesamorelin 5 mg Vial for Visceral Fat Research
Injection · 5mg · vial
Axiolabs Tesamorelin is a stabilised GHRH analog, approved in injectable form for visceral fat in lipodystrophy and studied for the growth hormone pulse it triggers. Supplied as a powder in a 5 mg vial.
GMP-manufactured, HPLC-verified per batch with the COA on file. Tesamorelin for sale with international shipping; the product page shows current availability.
Product overview
Axiolabs Tesamorelin 5 mg Research Vial
Axiolabs Tesamorelin is a stabilised GHRH analog, supplied as a research powder in a 5 mg vial. It acts on the pituitary GHRH receptor and raises endogenous growth hormone and IGF-1 transiently, and it is the one peptide of this cluster with an approved injectable form, sold as Egrifta for visceral fat in patients with HIV-associated lipodystrophy. That approval belongs to the prescription product and not to this vial. The older, shorter GHRH fragment Sermorelin is the natural comparison.
- 5 mg of tesamorelin per vial
- Lyophilized research powder - needs a solvent
- GMP-manufactured - HPLC-verified per batch, COA on file
- International shipping with discreet plain packaging
How Tesamorelin Works
The peptide binds GHRH receptors on pituitary cells and produces a short rise in growth hormone and IGF-1. It clears quickly: the label of the approved form reports an average half-life of about 8 minutes after a 1.4 mg subcutaneous dose for Egrifta SV and about 11 minutes for the WR version, while general data quote 26 to 38 minutes. Daily injection follows from that. The ghrelin receptor is not involved, so Ipamorelin and this peptide are different arms rather than substitutes.
Dosage & Reconstitution
Approved dosing belongs to the prescription product: 2 mg daily for Egrifta and 1.4 mg daily for Egrifta SV, by subcutaneous injection. With the research vial the arithmetic matters more than a schedule: divide the milligrams on the label by the millilitres of bacteriostatic water added, so 5 mg with 2 mL gives 2.5 mg/mL. One 5 mg vial does not cover a week at the approved dose, and a longer-acting analog such as CJC-1295 no DAC is the arm used when fewer injections are wanted.
Quality & Authenticity
Each batch is produced under GMP conditions and verified by third-party HPLC, with a Certificate of Analysis held for the batch. International orders leave in discreet plain packaging, and the product page shows current stock, which at the time of writing is out of stock.
For laboratory research only. Consult a healthcare professional before handling any peptide.
Specifications
| Trade Name | Tesamorelin |
| Generic Name | Tesamorelin |
| Manufacturer | Axiolabs |
| Dosage | 5 mg per vial |
| Package | Single vial, research powder |
| Drug Class | GHRH analog peptide, research |
| Administration | Research use after reconstitution |
| Storage | Powder cold and dry; solution 2-8 C, do not freeze |
| Prescription Status | Research use only; not for human use |
| Verification | Third-party HPLC per batch, COA on file |
| Shipping | International 4-10 days |
Stacks
For laboratory research only. Consult a healthcare professional before handling any peptide. Amounts shown are research references, not recommended human doses.
FAQ
Before you ask
Questions, answered
Tesamorelin is a stabilised GHRH analog that raises endogenous growth hormone and IGF-1. Its prescription form, Egrifta, is approved for visceral fat in patients with HIV-associated lipodystrophy and is injected daily. The vial on this page is a research material and not that medicine. In sport the peptide is named directly in class S2 of the WADA Prohibited List and is banned at all times.
Very short. The label of the approved form reports an average half-life of about 8 minutes after a 1.4 mg subcutaneous dose of Egrifta SV and about 11 minutes for the WR version, while general data give 26 to 38 minutes. The short window is why the clinical schedule is one injection every day rather than a weekly one, and why a single daily dose does not keep growth hormone elevated around the clock.
In the approved population it was studied for that endpoint with long daily treatment, and visceral fat reduction was recorded in clinical data. That evidence belongs to the prescription product used in patients with lipodystrophy; it does not transfer to healthy users and it says nothing about a research vial. The 5 mg vial also falls short of a week at the approved dose, which is arithmetic rather than a comment on effect.
Add bacteriostatic water down the side of the vial and swirl it gently instead of shaking; never add water to a stream of powder. A 5 mg vial with 2 mL gives 2.5 mg/mL, so the millilitres you add set the concentration you read on a syringe. Keep the sealed powder cold, dry and out of light, hold the dissolved solution at 2-8 C, and do not freeze it.
Injection site reactions are the most frequent effect of the injected class, followed by edema and fluid retention, joint and muscle aches, and headache. Growth hormone stimulation also means glucose handling and IGF-1 are worth watching, and the clinical product is monitored for those. No validated human safety profile exists for the research vial, so the class description is the only guidance available here.
The 5 mg vial is listed on this page and the product page shows current availability and price; at the time of writing the vial is out of stock, so check the listing for restocking rather than expecting same day dispatch. International shipping is about 45 dollars, with orders handled in one to two business days and transit of four to ten days. Each batch is GMP-manufactured and HPLC-verified with the COA on file.
Be the first to share your experience with Axiolabs Tesamorelin 5 mg Vial for Visceral Fat Research
Log in to write a reviewComplete the cycle